The value of pharma schemes rose as investors shifted focus to drugmakers, considered defensive in uncertain times. As per data from Value Research the mid-cap category offered the highest return of 8.93%, followed by multi-caps which returned 7.88%.
PB Fintech: Goldman Sachs, Tata Mutual Fund buy stake in Rs 695 crore block deal
PB Fintech shares witnessed block deals worth Rs 695 crore, with Goldman Sachs, mutual funds, and foreign investors acquiring shares from Tencent Cloud Europe, signaling